超高速剂量率临床试验中FLASH效应质量保证框架及当前技术差距
本报告由NRG Oncology放射肿瘤学创新中心FLASH工作组提出,针对超高速剂量率(UHDR)临床试验的质量保证与设备认证初步框架,涵盖UHDR束流参数、安全递送、剂量学技术、系统与站点认证及治疗计划等新要求,并综述当前技术差距与FLASH-RT主要问题及下一步方向。FLASH-RT有潜力但伴随显著风险与复杂性,需重新定义优化以同时关注剂量与剂量率。
要点
- UHDR临床试验中设备与参与站点的质量保证和认证对结果有效性至关重要。
- 报告提出治疗系统标准分析、患者定位和治疗计划的新质量保证要求。
- FLASH-RT有潜力但伴随显著风险与复杂性,需重新定义优化同时关注剂量与剂量率。
核心结论
- FLASH-RT有潜力但伴随显著风险与复杂性,需重新定义优化以同时关注剂量与剂量率,并以稳健、可理解、可处方、可验证和可实时确认的方式进行。
- 稳健的患者安全系统和治疗数据获取对FLASH-RT进入临床试验至关重要。
研究设计与样本
- 本报告为NRG Oncology放射肿瘤学创新中心FLASH工作组提出的UHDR临床试验质量保证初步框架,并综述当前需克服的技术差距。
主要发现
- UHDR束流递送参数覆盖电子与质子模态,并讨论安全UHDR束流递送的定义与控制及当前与所需的剂量学技术。
- 综述了大型多机构试验的系统与站点认证,并提出治疗系统标准分析、患者定位和治疗计划的新质量保证要求。
- 文中表格与图作为迈向FLASH-RT临床试验实施的参考点,并讨论了FLASH-RT若干主要问题及该领域下一步方向。
局限性
- FLASH-RT有潜力但伴随显著风险与复杂性。
- 需重新定义优化以同时关注剂量与剂量率,并以稳健、可理解、可处方、可验证和可实时确认的方式进行。
- 稳健的患者安全系统和治疗数据获取对FLASH-RT进入临床试验至关重要。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
FLASH radiation therapy (FLASH-RT), delivered with ultrahigh dose rate (UHDR), may allow patients to be treated with less normal tissue toxicity for a given tumor dose compared with currently used conventional dose rate. Clinical trials are being carried out and are needed to test whether this improved therapeutic ratio can be achieved clinically. During the clinical trials, quality assurance and credentialing of equipment and participating sites, particularly pertaining to UHDR-specific aspects, will be crucial for the validity of the outcomes of such trials. This report represents an initial framework proposed by the NRG Oncology Center for Innovation in Radiation Oncology FLASH working group on quality assurance of potential UHDR clinical trials and reviews current technology gaps to overcome. An important but separate consideration is the appropriate design of trials to most effectively answer clinical and scientific questions about FLASH. This paper begins with an overview of UHDR RT delivery methods. UHDR beam delivery parameters are then covered, with a focus on electron and proton modalities. The definition and control of safe UHDR beam delivery and current and needed dosimetry technologies are reviewed and discussed. System and site credentialing for large, multi-institution trials are reviewed. Quality assurance is then discussed, and new requirements are presented for treatment system standard analysis, patient positioning, and treatment planning. The tables and figures in this paper are meant to serve as reference points as we move toward FLASH-RT clinical trial performance. Some major questions regarding FLASH-RT are discussed, and next steps in this field are proposed. FLASH-RT has potential but is associated with significant risks and complexities. We need to redefine optimization to focus not only on the dose but also on the dose rate in a manner that is robust and understandable and that can be prescribed, validated, and confirmed in real time. Robust patient safety systems and access to treatment data will be critical as FLASH-RT moves into the clinical trials.
引用
- Zou W, Zhang R, Schüler E, et al. Framework for Quality Assurance of Ultrahigh Dose Rate Clinical Trials Investigating FLASH Effects and Current Technology Gaps. Int J Radiat Oncol Biol Phys. 2023. PMID: 37121362. doi:10.1016/j.ijrobp.2023.04.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。